Haemonetics (STU:HAZ) Beta: 0.8788 (As of Jul. 01, 2026)


STU:HAZ Haemonetics Corp STU:HAZ
25 GF Score
Price €65.50
GF Value €74.16
! 4 Warning Signs
View Full Analysis

What is Haemonetics Beta?

Haemonetics STU:HAZ 25 Beta is 0.8788 as of Jul. 01, 2026. GuruFocus rates STU:HAZ with a GF Score™ of 25/100 and a GF Value™ of €74.16. The stock has 4 warning signs investors should review.

Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. As of today (2026-07-01), Haemonetics's Beta is 0.8788.


Haemonetics  (STU:HAZ) Beta Explanation

Beta is a measure of the volatility, or systematic risk, of a security or a portfolio in comparison to the market as a whole. We usually compare beta to 1. A beta of 1 indicates that the security's price will move with the market. A beta of less than 1 means that the security will be less volatile than the market. A beta of greater than 1 indicates that the security's price will be more volatile than the market.

Beta is primarily used in the Capital Asset Pricing Model (CAPM) to calculate the Cost of Equity, which can be used in the calculation of WACC %. The formula of Cost of Equity is:
Cost of Equity = Risk-Free Rate of Return + Beta of Asset * (Expected Return of the Market - Risk-Free Rate of Return)


Haemonetics Beta Related Terms


Haemonetics Beta Historical Data

* Premium members only.

The historical data trend for Haemonetics's Beta can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Haemonetics Beta Chart

Haemonetics Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Beta
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.14 0.04 0.06 0.17 0.50

Haemonetics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Beta Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.17 0.43 0.51 -0.84 0.50

STU:HAZ vs ITGR, IRTC, ESTA: Beta Comparison

For the Medical Devices subindustry, Haemonetics's Beta, along with its competitors' market caps and Beta data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Haemonetics Beta vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Haemonetics's Beta distribution charts can be found below:

* The bar in red indicates where Haemonetics's Beta falls into.


STU:HAZ
25GF Score
Haemonetics Corp STU:HAZ
Beta is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Haemonetics Beta Calculation

Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. A stock's beta can be calculated by dividing the product of the covariance of the individual stock's returns and the market's returns by the variance of the market's returns over a specified period. Basically, GuruFocus uses the returns calculated over three-year period.

Frequently Asked Questions Learn more about Beta →
What does a Beta of 0.8788 mean?
Haemonetics (STU:HAZ) has a Beta of 0.8788 as of Jul. 01, 2026. Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. View historical data for Haemonetics and its competitors.
Is Haemonetics' Beta too high?
Haemonetics' current Beta is 0.8788. Overall, Haemonetics has a GF Score™ of 25/100, reflecting its overall financial health beyond just this single metric.
How does Haemonetics' Beta compare to ITGR and IRTC?
Haemonetics' Beta of 0.8788 can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beta for a Medical Devices & Instruments company?
A good Beta depends on the Medical Devices & Instruments industry context. However, Beta should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beta mean?
A high Beta can signal that a stock is expensive relative to its fundamentals. Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. View historical data for Haemonetics and its competitors. Haemonetics's current Beta is 0.8788. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Haemonetics stock overvalued right now?
Haemonetics (STU:HAZ) has a current Beta of 0.8788. The stock's GF Value™ is €74.16, compared to a current price of €65.50 — trading 11.7% below its estimated fair value. The current Beta is 0.8788. Haemonetics' overall GF Score™ is 25/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beta calculated?
Beta is calculated from a company's financial statements. For Haemonetics (STU:HAZ), the current Beta is 0.8788 as of Jul. 01, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Haemonetics (STU:HAZ) Overvalued in 2026?

Based on GuruFocus' analysis, Haemonetics stock appears to be undervalued. The current stock price of €65.50 is trading 11.7% below its estimated GF Value™ of €74.16.

Key valuation signals for STU:HAZ:

  • Beta: 0.8788
  • GF Value™: €74.16 vs. price of €65.50 (11.7% below fair value)
  • GF Score™: 25/100 with 4 warning signs

No single metric tells the full story. See the STU:HAZ stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Haemonetics Business Description

Other Exchanges HAE:USA
Address 125 Summer Street, Boston, MA, USA, 02110
Haemonetics Corp aims to improve patient care and reduce the cost of healthcare by providing medical products and solutions in the blood and plasma component collection, surgical suite, and hospital transfusion service spaces. As such, the company operates under three segments: plasma, blood center, and hospital. The company emphasizes its plasma and hospital segments due to their robust growth potential, whereas the blood center segment tends to be constrained by higher competition. Product revenue is driven by demand for disposable blood component collection and processing sets and the related equipment needed for proper functionality.
25GF Score

Get the complete analysis for STU:HAZ

Beta is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€65.50
Price
€74.16
GF Value